Activation of Cl- currents in cultured rat retinal pigment epithelial cells by intracellular applications of inositol-1,4,5-triphosphate: differences between rats with retinal dystrophy (RCS) and normal rats.
Using the whole-cell configuration of the patch-clamp technique, we studied the conditions necessary for the activation of Cl--currents in retinal pigment epithelial (RPE) cells from rats with retinal dystrophy (RCS) and nondystrophic control rats. In RPE cells from both rat strains, intracellular application of 10 microM inositol-1, 4,5-triphosphate (IP3) via the patch pipette led to a sustained activation of voltage-dependent Cl- currents, blockable by 1 mm 4, 4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS). IP3 activated Cl- currents in the presence of a high concentration of the calcium chelator BAPTA (10 mM) in the pipette solution, but failed to do so when extracellular calcium was removed. Intracellular application of 10(-5)M Ca2+ via the patch pipette also led to a transient activation of Cl- currents. When the cells were preincubated in a bath solution containing thapsigargin (1 microM) for 5 min before breaking into the whole-cell configuration, IP3 failed to activate voltage-dependent currents. Thus, IP3 led to release of Ca2+ from cytosolic calcium stores. This in turn activated an influx of extracellular calcium into the submembranal space by a mechanism as yet unknown, leading to an activation of calcium-dependent chloride currents. In RPE cells from RCS rats, which show an increased membrane conductance for calcium compared to normal rats, we observed an accelerated speed of Cl--current activation induced by IP3 which could be reduced by nifedipine (1 microM). Thus, the increased membrane conductance to calcium in RPE cells from RCS rats changes the response of the cell to the second messenger IP3.
Strauss
O
O
CNS Pharmakology, Boehringer Ingelheim, Binger Strasse, 55216 Ingelheim am Rhein, Germany.
Wiederholt
M
M
Wienrich
M
M
D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid / Q000494:pharmacology; D000818:Animals; D002118:Calcium / Q000494:pharmacology; D002614:Chelating Agents / Q000494:pharmacology; D018118:Chloride Channels / Q000187:drug effects* / Q000502:physiology; D002712:Chlorides / Q000378:metabolism*; D004533:Egtazic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D004558:Electric Stimulation; D015544:Inositol 1,4,5-Trisphosphate / Q000494:pharmacology* / Q000502:physiology; D007424:Intracellular Fluid / Q000378:metabolism; D008845:Microinjections; D018408:Patch-Clamp Techniques; D010857:Pigment Epithelium of Eye / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D011922:Rats, Mutant Strains; D012162:Retinal Degeneration / Q000378:metabolism / Q000473:pathology*; D015290:Second Messenger Systems / Q000502:physiology*
D002614:Chelating Agents; D018118:Chloride Channels; D002712:Chlorides; D004533:Egtazic Acid; D015544:Inositol 1,4,5-Trisphosphate; C025603:1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; D002118:Calcium